What it is

LL-37 is a human antimicrobial peptide derived from the cathelicidin precursor (often referred to as cathelicidin LL‑37). It’s part of the body’s innate immune toolkit and is studied for how it interacts with microbial membranes.

Why people care about it

LL-37 is interesting because it sits at the intersection of two big themes:

Direct antimicrobial action (membrane disruption and other mechanisms)
Immune signaling (peptides that act like native “messages” as well as defenses)

What we know vs what we don’t know

What we know:

LL‑37 has extensive preclinical literature as a membrane-active antimicrobial peptide.
Combinations with other innate peptides may change potency and cytotoxicity in ways that suggest tunable “design rules.”

What we don’t know:

Whether LL‑37-like approaches can become safe, reliable therapeutics at the doses and delivery routes required for real infections.

Latest updates

2026-04-08: A bioRxiv preprint reported that adding/transposing an N-terminal biphenyl motif from full-length LL-37 onto short cathelicidin fragments increased gram-negative activity by >16-fold, with follow-on stability modifications explored. https://www.biorxiv.org/content/10.1101/2025.05.22.655619v3
2026-04-02: A mechanistic study proposed that LL‑37 and HNP1 form reversible aggregates whose behavior depends on membrane lipid composition, helping explain how the combination can be more antibacterial and less cytotoxic. https://pubmed.ncbi.nlm.nih.gov/41923698/

Safety reality

LL‑37 is not an approved antibiotic. Treat any non-regulated products claiming to be LL‑37 as high risk.